A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients

Cancer Research

Volumn 65, Issue 10, 2005, Pages 4059-4066

  Dai, Hongyue ^a   Van't Veer, Laura ^b   Lamb, John ^a   He, Yudong D ^a   Mao, Mao ^a   Fine, Bernard M ^c   Bernards, Rene ^b   Van De Vijver, Marc ^b   Deutsch, Paul ^c   Sachs, Alan ^a   Stoughton, Roland ^a,d   Friend, Stephen ^a,c  

^a ROSETTA INPHARMATICS   (United States)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c MERCK RESEARCH LABORATORIES   (United States)

^d GHC Technologies Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR;

ADULT; AGE; ARTICLE; BREAST CANCER; CANCER PATIENT; CELL CYCLE; CELL PROLIFERATION; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; METASTASIS POTENTIAL; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROBABILITY; PROTEIN EXPRESSION;

AGE FACTORS; BREAST NEOPLASMS; CELL CYCLE; CELL GROWTH PROCESSES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; NEOPLASM METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RECEPTORS, ESTROGEN;

EID: 20144374709     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3953     Document Type: Article

References (35)

1. Zajchowski DA, Bartholdi MF, Gong Y, et al. Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. Cancer Res 2001;61:5168-78.
2. West M, Blanchette C, Dressman H, et al. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci U S A 2001;98: 11462-7.
3. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
4. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418-23.
5. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406: 747-52.
6. Khan J, Simon R, Bittner M, et al. Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Res 1998;58:5009-13.
7. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999;286:531-7.
8. DeRisi J, Penland L, Brown PO, et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet 1996;14:457-60.
9. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-11.
10. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 2004; 113:913-23.
11. Ishibashi Y, Hanyu N, Nakada K, et al. Profiling gene expression ratios of paired cancerous and normal tissue predicts relapse of esophageal squamous cell carcinoma. Cancer Res 2003;63:5159-64.
12. Latil A, Bieche I, Chene L, et al. Gene expression profiling in clinically localized prostate cancer: a four-gene expression model predicts clinical behavior. Clin Cancer Res 2003;9:5477-85.
13. Pang ST, Dillner K, Wu X, et al. Gene expression profiling of androgen deficiency predicts a pathway of prostate apoptosis that involves genes related to oxidative stress. Endocrinology 2002;143:4897-906.
14. Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002;8:816-24.
15. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
16. Gruvberger S, Ringner M, Chen Y, et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 2001;61:5979-84.
17. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 2003;100:10393-8.
18. Surowiak P, Dziegiel P, Zabel M, Matkowski R, Kornafel J. Prognostic value of immunocytochemical estimation of estrogen receptor (ER) and of pS2 estrogen-dependent protein in cells of mammary ductal carcinoma. Analysis of five-year course of the disease. Folia Histochem Cytobiol 2001;39:143-4.
19. Pichon MF, Broet P, Magdelenat H, et al. Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers. Br J Cancer 1996;73: 1545-51.
20. Collett K, Hartveit F, Skjaerven R, Maehle BO. Prognostic role of oestrogen and progesterone receptors in patients with breast cancer: relation to age and lymph node status. J Clin Pathol 1996;49:920-5.
21. Maggard MA, O'Connell JB, Lane KE, et al. Do young breast cancer patients have worse outcomes? J Surg Res 2003;113:109-13.
22. Foulkes WD, Metcalfe K, Sun P, et al. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 2004;10:2029-34.
23. van Diest PJ, van der Wall E, Baak JP. Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol 2004;57:675-81.
24. Simpson JF, Gray R. Dressier LG, et al. Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: results from the Eastern Cooperative Oncology Group Companion Study, EST 4189. J Clin Oncol 2000;18:2059-69.
25. Bijker N, Peterse JL, Duchateau L, et al. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol 2001;19: 2263-71.
26. Mirza AN, Mirza NQ, Vlastos G, Singletary SE. Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg 2002;235: 10-26.
27. Reed W, Hannisdal E, Boehler PJ, et al. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years. Cancer 2000;88:804-13.
28. Freund Y. Boosting a weak learning algorithm by majority. Information Comput 1995;121;256-85.
29. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
30. Kaufmann M. Review of known prognostic variables. Recent Results Cancer Res 1996;140:77-87.
31. Whitfield ML, Sherlock G, Saldanha AJ, et al. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell 2002;13:1977-2000.
32. Liu S, Edgerton SM, Moore DH U, Thor AD. Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer. Clin Cancer Res 2001;7:1716-23.
33. Medri L, Volpi A, Nanni O, et al. Prognostic relevance of mitotic activity in patients with node-negative breast cancer. Mod Pathol 2004;17:1024.
34. Michels JJ, Marnay J, Delozier T, Denoux Y, Chasle J. Proliferative activity in primary breast carcinomas is a salient prognostic factor. Cancer 2004;100:455-64.
35. Pittman J, Huang E, Dressman H, et al. Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. Proc Natl Acad Sci U S A 2004;101:8431-6.